129,173 views
Big Pharma, investments, a controversial drug and patients who become test subjects. Nieuwsuur revealed how doctors and pharmaceutical companies work so closely together in the development of a controversial Alzheimer's drug that, according to experts, they give the impression of a conflict of interest. How do pharmaceutical companies work together with academic doctors and hospitals? How do patients become test subjects? And how is it possible that director Philip Scheltens of the Dutch Alzheimer Center also works for a commercial company that examines patients for the pharmaceutical industry? In this video, Siebe Sietsma takes you through the long search he made with Machteld Veen for answers to these questions. A search that takes you from the Amsterdam UMC, via an American pharmaceutical company back to a Dutch investment fund. #alzheimer #bigpharma #research *********************************************************************************************************** Read the full responses and an explanation of our research here: https://nos.nl/nieuwsuur/artikel/2401... Watch the entire interview with neurologist Philip Scheltens here: https://nos.nl/nieuwsuur/artikel/2401...